Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New research on breast cancer from P. Poletti and co-authors summarized
January 29th, 2009
"Aims and background. We conducted a feasibility Study to determine the safety and efficacy of liposome-encapsulated doxorubicin (Myocet) and vinorelbine in previously treated metastatic breast cancer patients," scientists in Bergamo, Italy report. "Liposome-encapsulated doxorubicin (30 mg/m(2)) Plus Vinorelbine (25 mg/m(2)) on days I and 8, every 3 weeks were given until disease progression, sever toxicity or up to 9 cycles. All patients underwent tumor assessment before enrollment. Patients with a life expectancy longer than 3 months and measurable or assessable disease were eligible. Twenty-one patients were included. Median number of treatment cycles was 5 (range,...
Source: Women's Health Weekly (2009-01-29)
|
